Eiger BioPharmaceuticals Receives FDA Rare Pediatric Disease (RPD) Designation for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies and Plans NDA Filing in 2019

Author's Avatar
Oct 22, 2018
Article's Main Image

- Designation Enables Priority Review Voucher Eligibility Upon NDA Approval

PR Newswire